NF-κB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins

Experimental and Molecular Pathology

Volumn 81, Issue 2, 2006, Pages 123-130

  Santhi, W S ^a   Sebastian, Paul ^b   Varghese, Bipin T ^b   Prakash, Om ^c   Pillai, M Radhakrishna ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^b REGIONAL CANCER CENTRE   (India)

^c GOVERNMENT DENTAL COLLEGE   (India)

Author keywords

COX 2; Minimal residual disease; NF B; Oral cancer

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYTOPLASM PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOLECULAR MARKER; CYCLOOXYGENASE 2; MEMBRANE PROTEIN; PTGS2 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MINIMAL RESIDUAL DISEASE; MOUTH CANCER; NUCLEAR LOCALIZATION SIGNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VALIDATION PROCESS; COMPARATIVE STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; METABOLISM; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYCLOOXYGENASE 2; CYTOPLASM; DISEASE PROGRESSION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM, RESIDUAL; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33750884111     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2006.05.001     Document Type: Article

References (41)

1. Baeuerle P.A., and Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12 (1994) 141-179
2. Barkett M., and Gilmore T.D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 8 (1999) 6910-6924
3. Boolbol S.K., Dannenberg A.J., Chadburn A., Martucci C., Guo X.J., Ramonetti J.T., Abreu-Goris M., Newmark H.L., Lipkin M.L., DeCosse J.J., and Bertagnolli M.M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56 (1996) 2556-2560
4. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., Edelstein D., Soslow R.A., Koki A.T., Woerner B.M., Masferrer J.L., and Dannenberg A.J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59 (1999) 991-994
5. Cogswell P.C., Guttridge D.C., Funkhouser W.K., and Baldwin Jr. A.S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19 (2000) 1123-1131
6. de Martin R., Schmid J.A., and Hofer-Warbinek R. The NF-Kappa B/Rel family of transcription factors in oncogenic transformation and apoptosis. Mutat. Res. 437 (1999) 231-243
7. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
8. Gallois C., Habib A., Tao J., Moulin S., Maclouf J., Mallat A., and Lotersztajn S. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J. Biol. Chem. 273 (1998) 23183-23190
9. Guo S.P., Wang W.L., Zhai Y.Q., and Zhao Y.L. Expression of nuclear factor-kappa B in hepatocellular carcinoma and its relation with the X protein of hepatitis B virus. World J. Gastroenterol. 7 (2001) 340-344
10. Hla T., and Neilson K.O. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7384-7388
11. Kaltschmidt B., Linker R.A., Deng J., and Kaltschmidt C. Cyclooxygenase-2 is a neuronal target gene of NF-κB. BMC Mol. Biol. 3 (2002) 1-16
12. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappa B in cancer: from innocent bystander to major culprit. Nat. Rev., Cancer 2 (2002) 301-310
13. Kojima M., Morisaki T., Izuhara K., Uchiyama A., Matsunari Y., Katano M., and Tanaka M. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 19 (2000) 1225-1231
14. Kovacs A.F. Relevance of positive margins in case of adjuvant therapy of oral cancer. Int. J. Oral Maxillofac. Surg. 33 (2004) 447-453
15. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 (2001) 429-434
16. Kwong D., Sham J., and Choy D. The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients. Int. J. Radiat. Oncol. Biol. Phys. 30 (1994) 1029-1036
17. La Rosa F.A., Pierce J.W., and Sonenshein G.E. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol. Cell. Biol. 14 (1994) 1039-1044
18. Lakshmi S., Nair M.B., Jayaprakash P.G., Rajalekshmy T.N., Nair M.K., and Pillai M.R. p53 protein and tumorigenesis in the uterine cervix. Gen. Diagn. Pathol. 142 (1997) .281-287
19. Leemans C.R., Tiwari R., Nauta J.J., van der Waal I., and Snow G.B. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73 (1994) 187-190
20. Lim J.W., Kim H., and Kim K.H. Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab. Invest. 81 (2001) 349-360
21. Lodi G., Sardella A., Bez C., Demarosi F., and Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J. Dent. Educ. 66 (2002) 896-902
22. Martinez J., Sanchez T., and Moreno J.J. Role of prostaglandin H synthase-2-mediated conversion of arachidonic acid in controlling 3T6 fibroblast growth. Am. J. Physiol. 273 (1997) 1466-1471
23. Moraitis D., Du B., De Lorenzo M.S., Boyle J.O., Weksler B.B., Cohen E.G., Carew J.F., Altorki N.K., Kopelovich L., Subbaramaiah K., and Dannenberg A.J. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 65 (2005) 664-670
24. Nair A., Venkatraman M., Maliekal T.T., Nair B., and Karunagaran D. NF-κB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22 (2003) 50-58
25. Nakayama H., Ikebe T., Beppu M., and Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92 (2001) 3037-3044
26. Pahl H.L. Activators and target genes of Rel/NF-kappa B transcription factors. Oncogene 18 (1999) 6853-6866
27. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of eighteen major cancers. Int. J. Cancer 54 (1993) 594-606
28. Ristimaki A., Honkanen N., Jankala H., Sipponen P., and Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57 (1997) 1276-1280
29. Sheng G.G., Shao J., Sheng H., Hooton E.B., Isakson P.C., Morrow J.D., Coffey Jr R.J., DuBois R.N., and Beauchamp R.D. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 113 (1997) 1999-2003
30. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
31. Sonenshein G.E. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin. Cancer Biol. 8 (1997) 113-119
32. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., and Sonenshein G.E. Aberrant nuclear factor-kappa B/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100 (1997) 2952-2960
33. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends. Pharmacol. Sci. 24 (2003) 96-102
34. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., DeVito B., Weksler B.B., and Dannenberg A.J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56 (1996) 4424-4429
35. Thanos D., and Maniatis T. NF-kappa B: a lesson in family values. Cell 80 (1995) 529-532
36. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T., and Fahey 3rd T.J. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59 (1999) 987-990
37. van der Waal I., Schepman K.P., van der Meij E.H., and Smeele L.E. Oral leukoplakia: a clinicopathological review. Oral Oncol. 33 (1997) 291-301
38. van Houten V.M.M., Tabor M.P., van den Brekel M.W.M., Denkers F., Wishaupt R.G.A., Kummer J.A., Snow G.B., and Brakenhoff R.H. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin. Cancer Res. 6 (2000) 3803-3816
39. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., and Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5 (1999) 119-127
40. Wang W., Luo H.S., and Yu B.P. Expression of NF-κB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions. World J. Gastroenterol. 10 (2004) 177-181
41. Zhu J.W., Yu B.M., Ji Y.B., Zheng M.H., and Li D.H. Upregulation of vascular endothelial growth factor by hydrogen peroxide in human colon cancer. World J. Gastroenterol. 8 (2002) 153-157